HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PEGBIO CO-B

5.495

-0.195-3.43%

Volume:3.10M

Turnover:17.12M

Market Cap:2.15B

PE:-8.57

High:5.705

Open:5.690

Low:5.490

Close:5.690

52wk High:77.000

52wk Low:4.940

Shares:391.00M

HK Float Shares:386.00M

Volume Ratio:0.50

T/O Rate:0.80%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.641

ROE:-125.57%

ROA:-44.55%

PB:6.91

PE(LYR):-8.57

PS:-160.94

Loading ...

Overview Company News Filings

Pegbio publishes 2025 annual report

PegBio cornerstone investor holds 9,584,500 H shares, or 3.37% of H-share capital

PegBio: Cornerstone Investor Extends Lock-Up on 9.58 Million H Shares to 20 May 2026

Bulletin Express

PegBio Wins China Nod for Hong Kong Share Full Circulation

MT Newswires Live

PegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares

Bulletin Express

PEGBIO CO-B Receives CSRC Filing Notice for H-Share Full Circulation

PegBio receives CSRC filing notice for H-share full circulation of 101,702,051 shares

PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026

Bulletin Express

PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential

PegBio's CR059, a Potential Game-Changer in Metabolic Disease Treatment, Garners Prestigious Recognition at ADA Conference

PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059

Bulletin Express

PEGBIO CO-B's CR059 Research Abstract Accepted for Poster Presentation at ADA 2026 Scientific Sessions

PegBio says CR059 diabetes abstract accepted as ADA late-breaking poster presentation

PEGBIO CO-B Announces Appointment of Guo En-ting as Joint Company Secretary and Authorized Representative

PegBio Announces Company Secretary Reshuffle and Secures HKEX Waiver

Bulletin Express

PegBio appoints Kwok Yan Ting Jennis as joint company secretary, replacing Chow Shing Lung

BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 Million

PegBio Trims Losses in 2025

MT Newswires Live

PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings

Bulletin Express

PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/02565/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"PEGBIO CO-B","latestPrice":5.495,"timestamp":1788163726678,"preClose":5.69,"halted":0,"volume":3097850,"delay":0,"changeRate":-0.03427065026362044,"floatShares":386000000,"shares":391000000,"eps":-0.6413900536896971,"marketStatus":"Closed","change":-0.195,"latestTime":"08-31 16:08:46","open":5.69,"high":5.705,"low":5.49,"amount":17123803,"amplitude":0.037786,"askPrice":5.495,"askSize":19950,"bidPrice":5.49,"bidSize":37500,"shortable":3,"etf":0,"ttmEps":-0.995428034016538,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.69,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.504557,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":386000000,"roa":"-44.55%","roe":"-125.57%","lyrEps":-0.64139,"volumeRatio":0.504557,"shares":391000000,"dividePrice":0,"high":5.705,"amplitude":0.037786,"preClose":5.69,"low":5.49,"week52Low":4.94,"pbRate":"6.91","psRate":"-160.94","week52High":77,"institutionHeld":0,"latestPrice":5.495,"committee":0.305483,"eps":-0.6413900536896971,"divideRate":0,"volume":3097850,"delay":0,"ttmEps":-0.995428034016538,"open":5.69,"prevYearClose":69,"prevWeekClose":5.69,"prevMonthClose":5.36,"prevQuarterClose":5.33,"fiveDayClose":5.96,"twentyDayClose":5.39,"sixtyDayClose":8.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-08-28","current":-5.520238,"percent":1,"low":-87.782868,"twenty":-72.790068,"median":-56.898206,"eighty":-11.368021,"high":-5.766342,"avg":-43.693638,"sd":28.220965,"marketCap":2225310817},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-29","current":-13.590249,"twenty":-73.716985,"median":-61.274827,"eighty":-19.064042,"marketCap":3375119921},{"date":"2026-06-05","current":-12.579887,"twenty":-73.438012,"median":-61.206433,"eighty":-18.597951,"marketCap":3128732256},{"date":"2026-06-12","current":-11.565594,"twenty":-73.352041,"median":-60.919795,"eighty":-17.056006,"marketCap":2874522760},{"date":"2026-06-18","current":-9.622776,"twenty":-73.31105,"median":-60.791238,"eighty":-14.753422,"marketCap":2397391091},{"date":"2026-06-26","current":-7.824338,"twenty":-73.278872,"median":-60.512398,"eighty":-13.899973,"marketCap":1939813998},{"date":"2026-07-03","current":-8.984958,"twenty":-73.271235,"median":-60.431019,"eighty":-13.561687,"marketCap":2229221732},{"date":"2026-07-10","current":-11.252888,"twenty":-73.25947,"median":-60.210807,"eighty":-13.050401,"marketCap":2788482623},{"date":"2026-07-17","current":-10.458113,"twenty":-73.235067,"median":-60.159469,"eighty":-12.830773,"marketCap":2600758687},{"date":"2026-07-24","current":-10.046967,"twenty":-73.215248,"median":-60.107782,"eighty":-12.739192,"marketCap":2499074889},{"date":"2026-07-31","current":-8.411523,"twenty":-73.183292,"median":-59.862622,"eighty":-12.522041,"marketCap":2096250611},{"date":"2026-08-07","current":-10.298244,"twenty":-73.061453,"median":-59.675079,"eighty":-12.306772,"marketCap":2571426822},{"date":"2026-08-14","current":-9.745542,"twenty":-72.966779,"median":-59.367669,"eighty":-11.991332,"marketCap":2436500244},{"date":"2026-08-21","current":-9.169953,"twenty":-72.846173,"median":-58.454271,"eighty":-11.546541,"marketCap":2297662750},{"date":"2026-08-28","current":-5.766342,"twenty":-72.790068,"median":-56.898206,"eighty":-11.368021,"marketCap":2225310817}],"updateTime":1788183284650},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630884465","title":"Pegbio publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630884465","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630884465?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:52","pubTimestamp":1777384357,"startTime":"0","endTime":"0","summary":"PegBio annual report for 2025 highlighted transition toward commercialization following China marketing clearance for core GLP-1 drug PB-119  in November 2025.Commercial launch preparations continued across manufacturing, supply chain, market access, patient support, and academic promotion, with first-half 2026 targeted for initial sales.Company maintained focus on metabolic diseases, with plans to expand into adjacent chronic disease areas such as cardiovascular and gastrointestinal conditions.Pipeline progress continued, with PB-718 advanced in obesity and MASH development and multiple earlier-stage metabolic programs positioned for IND submissions or trial starts in 2026.PegBio reported no product sales revenue to date, with operating performance still shaped mainly by R&D and administrative spending.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL6Zz4zl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630377516","title":"PegBio cornerstone investor holds 9,584,500 H shares, or 3.37% of H-share capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2630377516","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630377516?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:10","pubTimestamp":1777371002,"startTime":"0","endTime":"0","summary":"PegBio disclosed cornerstone investor Yizekangrui Medical  will extend its lock-up on 9,584,500 H shares until May 20, 2026.Holding represents about 3.37% of PegBio’s issued H shares.Lock-up had been set to expire April 30, 2026 following earlier extensions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL6qfdtp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140595958","title":"PegBio: Cornerstone Investor Extends Lock-Up on 9.58 Million H Shares to 20 May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1140595958","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140595958?lang=en_us&edition=fundamental","pubTime":"2026-04-28 18:04","pubTimestamp":1777370669,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. disclosed on 28 April 2026 that cornerstone investor Yizekangrui Medical (HK) Limited has voluntarily prolonged its lock-up commitment on 9.58 million H shares—equivalent to 3.37% of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626150334","title":"PegBio Wins China Nod for Hong Kong Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=2626150334","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626150334?lang=en_us&edition=fundamental","pubTime":"2026-04-10 10:28","pubTimestamp":1775788125,"startTime":"0","endTime":"0","summary":"PegBio  said the China Securities Regulatory Commission has issued a filing notice for its Hong Kong share full circulation application, according to a Thursday bourse filing.Shares of the biotechnology company were up nearly 1% in Friday morning trade.The filing covers the conversion of about 101.7 million unlisted shares into Hong Kong shares.PegBio will apply to the Hong Kong stock exchange for the listing of the converted shares, with further details of the plan yet to be finalized.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186046639","title":"PegBio Receives CSRC Filing Notice for Conversion of 101.70 Million Unlisted Shares to H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1186046639","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186046639?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:47","pubTimestamp":1775731664,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. announced that it has obtained a filing notice from the China Securities Regulatory Commission (CSRC) dated 26 March 2026, confirming completion of filing for its H Share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151031921","title":"PEGBIO CO-B Receives CSRC Filing Notice for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1151031921","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151031921?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:30","pubTimestamp":1775730638,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that the company has received a filing notice from the China Securities Regulatory Commission (CSRC) dated March 26, 2026, regarding the implementation of an H-share...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","XBI","BK1161","161726","BK4581","02565","399441","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626888185","title":"PegBio receives CSRC filing notice for H-share full circulation of 101,702,051 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626888185","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626888185?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:26","pubTimestamp":1775730395,"startTime":"0","endTime":"0","summary":"PegBio received a filing notice dated March 26, 2026 from China securities regulator for its H-share full circulation plan.Filing covers conversion of 101,702,051 unlisted shares into H shares.PegBio plans to seek Hong Kong listing approval to allow trading of converted H shares on Main Board.Conversion must be completed within 12 months of March 26, 2026 or the filing will need to be refreshed.Implementation plan remains unfinished, with further updates expected as process advances.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLc8wwBW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183616961","title":"PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1183616961","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183616961?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:22","pubTimestamp":1775640134,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights: • Share Capital Stability: Registered share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184512860","title":"PegBio's CR059 Selection for ADA Late-Breaking Abstract Highlights Monthly-Dosing GLP-1 Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1184512860","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184512860?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:02","pubTimestamp":1775559779,"startTime":"0","endTime":"0","summary":"PegBio (02565) has drawn market attention back to its circRNA-LNP technology platform after its core pipeline candidate CR059 was selected as a Late-Breaking Abstract (LBA) for the American Diabetes...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4144","BK4590","GLP","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134240360","title":"PegBio's CR059, a Potential Game-Changer in Metabolic Disease Treatment, Garners Prestigious Recognition at ADA Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1134240360","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134240360?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:07","pubTimestamp":1775131625,"startTime":"0","endTime":"0","summary":"PegBio CO-B (02565) announced after market close on April 2nd that a research abstract for its self-developed innovative drug candidate, CR059, has been accepted for presentation at the American...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134587484","title":"PegBio Announces ADA 2026 Late-Breaking Abstract Acceptance for Once-Monthly GLP-1 Candidate CR059","url":"https://stock-news.laohu8.com/highlight/detail?id=1134587484","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134587484?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:25","pubTimestamp":1775129108,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. reported that its internally developed candidate CR059 has been accepted as a Late Breaking Abstract for poster presentation at the 2026 Scientific Sessions of the American Diabetes...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179308864","title":"PEGBIO CO-B's CR059 Research Abstract Accepted for Poster Presentation at ADA 2026 Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=1179308864","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179308864?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:20","pubTimestamp":1775128824,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced that a research abstract related to its self-developed innovative candidate product, CR059, has been accepted by the American Diabetes Association (ADA) for its 2026...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK4581","XBI","161726","BK4588","BK4585","BK1161","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624503124","title":"PegBio says CR059 diabetes abstract accepted as ADA late-breaking poster presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624503124","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624503124?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:12","pubTimestamp":1775128357,"startTime":"0","endTime":"0","summary":"PegBio disclosed that an abstract on CR059 was accepted for poster presentation at 2026 American Diabetes Association Scientific Sessions as a late-breaking abstract.Results have not yet been presented; presentation is scheduled during 2026 ADA meeting.Preclinical data in rhesus monkeys with type 2 diabetes showed durable glycemic control with weight-loss effects, supporting potential for long-acting metabolic disease treatment.Management highlighted expected monthly dosing potential, with a path to quarterly dosing, based on circRNA-LNP platform.Update signals rising external validation for PegBio metabolic disease pipeline, with CR059 still in research and development stage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. L","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLG15Kb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106026379","title":"PEGBIO CO-B Announces Appointment of Guo En-ting as Joint Company Secretary and Authorized Representative","url":"https://stock-news.laohu8.com/highlight/detail?id=1106026379","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106026379?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:10","pubTimestamp":1775041812,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that Mr. Zou Xinglong has resigned from his positions as Joint Company Secretary, Authorized Representative under Rule 3.05 of the Hong Kong Stock Exchange Listing...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","XBI","161726","399441","02565","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100737065","title":"PegBio Announces Company Secretary Reshuffle and Secures HKEX Waiver","url":"https://stock-news.laohu8.com/highlight/detail?id=1100737065","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100737065?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:04","pubTimestamp":1775041467,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. has disclosed a senior management change effective 1 April 2026. Joint Company Secretary, Authorised Representative and Process Agent Mr. Chow Shing Lung will step down, citing no...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624289597","title":"PegBio appoints Kwok Yan Ting Jennis as joint company secretary, replacing Chow Shing Lung","url":"https://stock-news.laohu8.com/highlight/detail?id=2624289597","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624289597?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:02","pubTimestamp":1775041346,"startTime":"0","endTime":"0","summary":"PegBio appointed Kwok Yan Ting Jennis as joint company secretary, authorized representative, process agent effective April 1, 2026.Kwok is senior manager, Entity Solutions at Computershare Hong Kong Investor Services with more than 12 years’ experience in corporate governance, company secretarial practice, regulatory compliance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL9mQGfS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK7157","BK7033","CPU.AU","02565","BK7503"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775537","title":"BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775537?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:49","pubTimestamp":1774262958,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Co Posts FY Loss Attributable RMB208.4 MillionMarch 23 (Reuters) - PegBio Co Ltd 2565.HK:FY LOSS ATTRIBUTABLE RMB208.4 MILLIONFurther company coverage: 2565.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621779352","title":"PegBio Trims Losses in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621779352?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:00","pubTimestamp":1774256439,"startTime":"0","endTime":"0","summary":"PegBio  booked 208.4 million yuan in attributable loss for 2025, narrowing from 283.4 million yuan in 2024, according to a Hong Kong bourse filing Monday.Loss per share was 0.55 yuan, compared with 0.77 yuan in the prior year.The firm did not generate any revenue during the year or in 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191587925","title":"PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191587925?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255349,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (PEGBIO CO-B, 02565) released its audited results for the year ended 31 December 2025. Financial Performance   • Loss for the year narrowed 26.4% to RMB208.55 million, versus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180038614","title":"PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=1180038614","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180038614?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255342,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced its annual results for the period ending December 31, 2025. The Group recorded other net income of RMB189,000 and research and development expenses of RMB50.387 million....","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4581","BK4585","399441","161726","XBI","BK4588","02565"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":120,"code":"91000000","status":"200"}]}}